Rosetta Genomics To Raise $6.6M In Registered Direct Offering

Rosetta Genomics, a developer and provider of microRNA-based molecular diagnostics, announced it has entered into definitive agreements with investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share in a registered direct offering. Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes. Founded in 2000, the company is headquartered in Rehovot, Israel, with labs in Philadelphia.